The findings of this study will lay the groundwork for prospective intervention trials with "tissue-specific" insulin-sensitizing agents, anti-inflammatory agents, and selective androgen receptor modulators (SARMs) [63] in preventing the development of insulin resistance during ADT, which in turn will lessen the burden of CVD in this population. Here, AR is linked to Insulin resistance.